Name: Recombinant Anti-CD64 x Anti-HIV-1 gp41 Bispecific Antibody (Fab-IgG)
SKU: FABIG-127
Rating: 5 (1 reviews)

Recombinant Anti-CD64 x Anti-HIV-1 gp41 Bispecific Antibody (Fab-IgG) is designed to be expressed as three chains, assembling in vivo and resulting in the construct of Fab-IgG (Tandem Fab-Fc). Fab-IgG has standard Fab and Fc domains, with no mutations, which may permit it has similar affinity binding and PK profile comparable to the parental antibodies. This BsAb can retarget neutrophils cells to HIV-1 infected cells. It is designed for the research of HIV-1 infection, AIDS therapy.

Datasheet INQUIRY

Specifications

Targets

CD64 & HIV-1 gp41

Type

Fab-IgG

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

HIV-1 infection, AIDS

Host Animal 1

Mouse

Host Animal 2

Mouse

Targets

Target 1

CD64

Gene ID

2209

UniProt ID

P12314

Alternative Names

FCGR1A; Fc fragment of IgG receptor Ia; CD64; FCRI; CD64A; IGFR1; Cluster of Differentiation 64; FcγRI; FCGR1B; FCGR1C; immunoglobulin G Fc receptor high affinity I; Fc gamma RI

Target 2

HIV-1 gp41

Gene ID

155971

UniProt ID

Q0H5Z9

Alternative Names

ENV; gp160; Envelope glycoprotein 120; envelope glycoprotein; Envelope surface glycoprotein gp160, precursor; hypothetical protein; Envelope surface glycoprotein gp120; Envelope transmembrane domain; human immunodeficiency virus type 1; human immunodeficiency virus type 1 gp120; human immunodeficiency virus type 1 glycoprotein 120; gp41; GP41; glycoprotein 41

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD64 x Anti-HIV-1 gp41 Bispecific Antibody (Fab-IgG) (FABIG-127). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD64 x Anti-HIV-1 gp41 Bispecific Antibody (Fab-IgG) (CAT#: FABIG-127)

Specifications

Targets

Customer Reviews and Q&As